Discover today's top 10 stocks in focus, key Q1 earnings, and major corporate actions - explore the latest market movers now!

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Lupin launches Ipratropium Bromide Nasal Solution in the US market; eyes expanding complex generics pipeline to over 200 ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets: Our Bureau, Mumbai Friday, July 4, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin ...

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are ...

Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...

Lupin launches Ipratropium Bromide nasal spray in US, bioequivalent to Atrovent. The product addresses rhinitis and targets a $63 million market opportunity.

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, ...

Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in ...

Getting a cold once or twice a few months is normal, but what about a persistently blocked nose that lingers for weeks and ...